68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Based on the high expression of specific receptors on the surface of diseased tissues and
neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions
in vitro by combining specific ligands labeled with short half-life isotopes. Lung cancer
tissues express fibroblast activating protein FAP, and also have high expression of integrin
αVβ3 receptor on the surface of blood vessels. In this study, a novel dual-target imaging
agent 68Ga-FAPI-RGD was used for PET/CT imaging of lung cancer.